Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b dose-finding study of single intravenous TIN816 in sepsis-associated acute kidney injury
CTR20240684Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of TIN-816 in sepsis-associated acute kidney injury (S-AKI), sponsored by Novartis. Started Mar 2024; status: completed.
02
Drugs
TIN-816
03
Conditions
sepsis-associated acute kidney injury (S-AKI)
Beyond the preview
Go deeper on CTR20240684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240684.